C Kent Osborne

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 12:362-7. 2003
  2. pmc Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
    C Kent Osborne
    Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1147-59. 2011
  3. pmc Mechanisms of endocrine resistance in breast cancer
    C Kent Osborne
    Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Annu Rev Med 62:233-47. 2011
  4. ncbi request reprint Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
  5. ncbi request reprint Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
  6. pmc Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008
  7. ncbi request reprint Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
  8. ncbi request reprint Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
    Yee Lu Tham
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:279-84. 2005
  9. ncbi request reprint Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    Jenny C Chang
    Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:1169-77. 2005
  10. pmc Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
    Albert C Chen
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res Treat 134:583-93. 2012

Research Grants

  1. TRANSLATIONAL RESEARCH IN BREAST CANCER
    C Osborne; Fiscal Year: 2007
  2. Baylor College of Medicine Cancer Center
    C Osborne; Fiscal Year: 2005
  3. TRANSLATIONAL RESEARCH IN BREAST CANCER
    C Osborne; Fiscal Year: 2007
  4. Baylor College of Medicine Cancer Center
    C Osborne; Fiscal Year: 2007

Collaborators

Detail Information

Publications80

  1. ncbi request reprint Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 12:362-7. 2003
    ..In turn, ER located in the cell membrane can activate the growth factor receptor pathways. Breast tumors with high levels of AIB1 and HER-2 may be resistant to tamoxifen because of an increase in its estrogen agonist activity...
  2. pmc Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
    C Kent Osborne
    Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1147-59. 2011
    ..This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)-positive metastatic breast cancer...
  3. pmc Mechanisms of endocrine resistance in breast cancer
    C Kent Osborne
    Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Annu Rev Med 62:233-47. 2011
    ..Results of recent clinical studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies...
  4. ncbi request reprint Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
    ..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models...
  5. ncbi request reprint Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
  6. pmc Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008
    ..Over time, the molecular phenotype of breast cancer can change...
  7. ncbi request reprint Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
    ..We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy...
  8. ncbi request reprint Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
    Yee Lu Tham
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:279-84. 2005
    ....
  9. ncbi request reprint Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    Jenny C Chang
    Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:1169-77. 2005
    ..Chemotherapy for operable breast cancer decreases the risk of death. Docetaxel is one of the most active agents in breast cancer, but resistance or incomplete response is frequent...
  10. pmc Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
    Albert C Chen
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res Treat 134:583-93. 2012
    ..These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive...
  11. ncbi request reprint Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
    Jenny C Chang
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    Breast Cancer Res Treat 108:233-40. 2008
    ..008). We have established molecular profiles of sensitivity to docetaxel. RT-PCR technology provides a potential platform for a predictive test of docetaxel chemosensitivity using small amounts of routinely processed material...
  12. ncbi request reprint Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance...
  13. pmc Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice
    Tracy E Strecker
    Breast Center, Department of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 101:107-13. 2009
    ..Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer...
  14. ncbi request reprint Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
    Syed K Mohsin
    Breast Center at Baylor College of Medicine The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:2460-8. 2005
    ..Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients...
  15. pmc Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
    Ilenia Migliaccio
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Room N1110, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:651-60. 2010
    ..0001) when compared with patients with PR-/IRS-1- tumors. In conclusion, nuclear IRS-1 may be a useful marker to predict tamoxifen response in patients with early breast cancer, particularly when assessed in combination with PR...
  16. doi request reprint Low SAFB levels are associated with worse outcome in breast cancer patients
    Stephanie Hammerich-Hille
    Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 121:503-9. 2010
    ..This study shows that low SAFB protein levels predict poor prognosis of breast cancer patients, suggesting critical functions of SAFB1 and SAFB2 in breast cancer cells...
  17. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  18. ncbi request reprint Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Xiaojiang Cui
    Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 23:7721-35. 2005
    ..Finally, we will consider the clinical implications of these observations...
  19. pmc β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
    Catherine Huang
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77054, USA
    Breast Cancer Res 13:R84. 2011
    ..The β1 integrin resides on the membrane of the breast cancer cell, activating several elements of breast tumor progression including proliferation and survival...
  20. ncbi request reprint Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
    Michelle D Martin
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Breast Cancer Res Treat 95:7-12. 2006
    ..Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies...
  21. pmc Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
    Mothaffar F Rimawi
    Lester and Sue Smith Breast Center, Margaret M and Albert B Alkek Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1351-61. 2011
    ....
  22. ncbi request reprint HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study
    Grazia Arpino
    Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Clin Cancer Res 10:5670-6. 2004
    ..Evidence of resistance from clinical studies has been inconsistent. The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen...
  23. ncbi request reprint Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
    ..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient...
  24. ncbi request reprint Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 56:10-20. 2005
    ....
  25. ncbi request reprint Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor
    Shiming Jiang
    The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 20:311-20. 2006
    ..The coexpression of these proteins in breast cancer specimens, and the combined recruitment (and release) of SAFB1/2 and N-CoR furthermore suggests that this interaction has functional relevance...
  26. ncbi request reprint Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
    ..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective...
  27. pmc Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
    Mothaffar F Rimawi
    Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Clin Oncol 31:1726-31. 2013
    ..In this clinical trial, we sought to translate these findings to patients using targeted therapy without chemotherapy...
  28. pmc Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers
    Bhuvanesh Dave
    Lester and Sue Smith Breast Center, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 29:166-73. 2011
    ..Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit...
  29. ncbi request reprint Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial
    Susan G Hilsenbeck
    Breast Center and Department of Medicine, Baylor College of Medicine, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Clin Cancer Res 12:1049s-1055s. 2006
    ..We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy...
  30. pmc Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
    Mothaffar F Rimawi
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cancer 116:1234-42. 2010
    ..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy...
  31. pmc Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance
    Grazia Arpino
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Endocr Rev 29:217-33. 2008
    ....
  32. ncbi request reprint Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    C Kent Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:353-61. 2003
    ....
  33. ncbi request reprint Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor
    Ashby J Morrison
    Department of Molecular and Cellular Biology and The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 17:1543-54. 2003
    ....
  34. ncbi request reprint Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
    Clin Cancer Res 11:865s-70s. 2005
    ..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials...
  35. ncbi request reprint Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer
    Torsten A Hopp
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Clin Cancer Res 10:7490-9. 2004
    ..The clinical value of the second recently identified ER isoform, called ER-beta, is less clear, and there is currently conflicting data concerning its potential role as a prognostic or predictive factor...
  36. ncbi request reprint The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
    Jana Divisova
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 98:315-27. 2006
    ..This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer...
  37. ncbi request reprint Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors
    Chunhua Lu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:1825-33. 2003
    ..We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer...
  38. pmc Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation
    Yen Chao Wang
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res 13:R121. 2011
    ..Here we investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive cell lines made resistant to these drugs...
  39. ncbi request reprint Estrogen-receptor biology: continuing progress and therapeutic implications
    C Kent Osborne
    Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
    J Clin Oncol 23:1616-22. 2005
  40. ncbi request reprint Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy
    C Kent Osborne
    The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 14:458-65. 2005
    ....
  41. pmc Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
    Gladys Morrison
    Lester and Sue Smith Breast Center and Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX, 77030, USA
    Breast Cancer Res Treat 144:263-72. 2014
    ..The absence of tumor regression, however, suggests that additional escape pathways contribute to resistant growth and will need to be targeted to fully circumvent tamoxifen resistance...
  42. doi request reprint Biological mechanisms and clinical implications of endocrine resistance in breast cancer
    Mario Giuliano
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast 20:S42-9. 2011
    ....
  43. pmc A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
    Jessica D Kessler
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Science 335:348-53. 2012
    ..Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers...
  44. pmc Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer
    Rachel Schiff
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 7:205-11. 2005
    ..Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials...
  45. ncbi request reprint Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    Valerie Jeanne Bardou
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:1973-9. 2003
    ..To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer...
  46. ncbi request reprint Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters
    Suzanne A W Fuqua
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 63:2434-9. 2003
    ..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right...
  47. pmc Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells
    Yihui Fan
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    J Pathol 232:75-86. 2014
    ....
  48. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  49. ncbi request reprint Aromatase inhibitors: future directions
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 95:183-7. 2005
    ....
  50. ncbi request reprint Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Jenny C Chang
    Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
    Lancet 362:362-9. 2003
    ..Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel...
  51. pmc Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
    Xiaoyong Fu
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Breast 22:S12-8. 2013
    ..Potential therapeutic approaches based on these findings are also discussed. ..
  52. ncbi request reprint Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
    ..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools...
  53. pmc Metastasis dormancy in estrogen receptor-positive breast cancer
    Xiang H F Zhang
    Authors Affiliations Lester and Sue Smith Breast Center, Dan L Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy McNair Medical Institute, Houston, Texas and Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy
    Clin Cancer Res 19:6389-97. 2013
    ..We also discuss future research directions toward a better understanding of the biologic mechanisms and clinical management of ER(+) dormant metastasis. Clin Cancer Res; 19(23); 6389-97. ©2013 AACR. ..
  54. ncbi request reprint Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancer
    Lois C Friedman
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
    J Behav Med 30:351-7. 2007
    ..89, p = .004, respectively). Patients may benefit from a discussion with their oncologists and other healthcare providers about self-forgiveness and the potential benefits of reducing self-blame to facilitate adjustment to breast cancer...
  55. pmc An epigenomic approach to therapy for tamoxifen-resistant breast cancer
    Qin Feng
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Cell Res 24:809-19. 2014
    ..Taken together, we provide evidence that the epigenomic proteins BRD3/4 and WHSC1 are essential regulators of estrogen receptor signaling and are novel therapeutic targets for treatment of Tam-R breast cancer. ..
  56. doi request reprint Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase
    Tingting Sun
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Cell 144:703-18. 2011
    ....
  57. ncbi request reprint Role of molecular and genetic markers in breast cancer treatment decisions
    C Kent Osborne
    Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:285s-287s. 2003
  58. ncbi request reprint Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth
    Yongmin Liu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston Texas, TX 77030, USA
    Oncogene 21:7680-9. 2002
    ..These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer...
  59. doi request reprint Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
    Xiaoxian Li
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
    J Natl Cancer Inst 100:672-9. 2008
    ....
  60. ncbi request reprint Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    Anthony Howell
    Christie Hospital and Holt Radium Institute, Manchester, UK
    J Clin Oncol 22:1605-13. 2004
    ....
  61. ncbi request reprint Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  62. ncbi request reprint Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance
    Susan Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Breast Cancer Res Treat 95:229-33. 2006
    ..We hypothesized that gene expression profiles predictive of AC response may be different from our previously published patterns with docetaxel...
  63. ncbi request reprint Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
    ..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal...
  64. ncbi request reprint The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer
    Xiao Jun Ma
    AviaraDx Inc, Carlsbad, CA, USA
    J Clin Oncol 24:4611-9. 2006
    ..Confirmation in larger independent patient cohorts was needed to fully validate their clinical utility...
  65. ncbi request reprint Enhanced gene expression in breast cancer cells in vitro and tumors in vivo
    Huanzhang Lu
    Center for Cell and Gene Therapy, National Cancer Institute, National Institutes of Health, Building 10, Room 2A27, Bethesda, Maryland 20892, USA
    Mol Ther 6:783-92. 2002
    ..Furthermore, expression profiling can facilitate the design of optimal expression plasmids for use in specific cancers...
  66. doi request reprint Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    Suleiman Massarweh
    Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 68:826-33. 2008
    ..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2...
  67. ncbi request reprint Insights into the role of progesterone receptors in breast cancer
    Suzanne A W Fuqua
    J Clin Oncol 23:931-2; author reply 932-3. 2005
  68. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    John F R Robertson
    Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
    Cancer 98:229-38. 2003
    ....
  69. ncbi request reprint Spreading the word, but not too thinly
    Anthony Howell
    Lancet 363:165-6. 2004
  70. ncbi request reprint Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  71. ncbi request reprint Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  72. ncbi request reprint Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer
    Lori J Pierce
    Southwest Oncology Group, San Antonio, TX, USA
    J Clin Oncol 23:24-9. 2005
    ..An exploratory analysis was undertaken to evaluate the optimal sequencing of TAM and radiotherapy (RT) after breast-conserving surgery...
  73. ncbi request reprint Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 11:861s-4s. 2005
  74. ncbi request reprint Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'
    Marc E Lippman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0368, USA
    Breast Cancer Res Treat 90:1-3. 2005
  75. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    Anthony Howell
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Cancer 104:236-9. 2005
    ..The authors reported the overall survival results from these studies...
  76. ncbi request reprint Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005
    ....
  77. ncbi request reprint Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer
    Li Hua Wang
    Basic Research Program, SAIC Frederick, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    Cancer Cell 10:487-99. 2006
    ..DIBA does not affect phosphorylation of HER2, MAPK, AKT, and AIB1, suggesting that DIBA-modified ERalpha may induce a switch from agonistic to antagonistic effects of TAM on resistant breast cancer cells...
  78. ncbi request reprint Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
    Hannah M Linden
    Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:656-61. 2007
    ....
  79. ncbi request reprint Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)
    Kishan J Pandya
    University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Am J Clin Oncol 30:113-25. 2007
    ....
  80. ncbi request reprint Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
    Saul E Rivkin
    Swedish Cancer Institute, Seattle, Washington, USA
    Cancer 97:21-9. 2003
    ....

Research Grants7

  1. TRANSLATIONAL RESEARCH IN BREAST CANCER
    C Osborne; Fiscal Year: 2007
    ..8) Our highly successful Developmental Projects Program and Career Development Program will continue to encourage new ideas and new investigators in translational breast cancer research. ..
  2. Baylor College of Medicine Cancer Center
    C Osborne; Fiscal Year: 2005
    ..To Develop Increased Support for Programs in the Shared Resources/Cores; and 4. To Recruit Additional Faculty to Strengthen Existing Programs and Support Additional Program Development. ..
  3. TRANSLATIONAL RESEARCH IN BREAST CANCER
    C Osborne; Fiscal Year: 2007
    ..8) Our highly successful Developmental Projects Program and Career Development Program will continue to encourage new ideas and new investigators in translational breast cancer research. ..
  4. Baylor College of Medicine Cancer Center
    C Osborne; Fiscal Year: 2007
    ....